Form 4: InMed Pharma Grants Options to Senior VP

InMed Pharmaceuticals Inc. has granted 8,500 employee stock options to Shane Aaron Johnson, Senior VP & General Manager, with an exercise price of $1.29.

Summary

• Shane Aaron Johnson, Senior VP & General Manager of InMed Pharmaceuticals Inc., was granted 8,500 employee stock options.
• The options have an exercise price of $1.29 per share.
• The grant date for these options is December 19, 2025.
• The options will vest in equal monthly installments over a 36-month period, starting from the grant date.
• The expiration date for these options is December 18, 2030.
• Following this transaction, Mr. Johnson beneficially owns a total of 12,400 derivative securities.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of stock options is a routine executive compensation event, aligning management incentives with shareholder value. It's not a major operational or financial announcement, but reflects ongoing corporate governance.

Positives

• Aligns management's interests with shareholder value through equity incentives.
• Provides a long-term incentive for the Senior VP & General Manager to contribute to the company's growth over the 36-month vesting period.

Negatives

• Potential for future share dilution if the options are exercised, though the amount is relatively small (8,500 shares).
• The value of the options is contingent on the stock price exceeding the $1.29 exercise price, introducing market risk.

Risks

• Market price volatility of InMed Pharmaceuticals Inc. common shares could render the options out-of-the-money, reducing their incentive value.
• The vesting schedule ties the executive to the company for 36 months, meaning the full benefit is not immediate and depends on continued employment.

Future Outlook

NA

Industry Context

Executive stock option grants are a standard practice in the biotechnology and pharmaceutical industry, as well as across many sectors, to incentivize management and align their performance with shareholder returns. The vesting schedule is typical for long-term retention.

Comparison to Industry Standards

• The grant of stock options to senior management is a common compensation practice across the pharmaceutical and biotech industry, similar to companies like Pfizer, Moderna, or smaller biotechs, to align executive incentives with long-term company performance.
• A 3-year vesting schedule is standard for such grants, comparable to practices seen in many publicly traded companies to ensure executive retention and sustained performance.
• The exercise price being set at the market price on the grant date (implied by $0.00 price of derivative security and common practice) is a standard approach for incentive stock options.

Related Party Transactions

• The grant of 8,500 employee stock options to Shane Aaron Johnson, a Senior VP & General Manager, constitutes a related party transaction as it involves an executive of the company.

Stakeholder Impact

• Shareholders: Potential minor dilution if options are exercised, but also potential for increased management alignment with shareholder interests.
• Employees: Reflects standard executive compensation practices, potentially signaling stability in leadership.

Next Steps

• The options will vest monthly over the next 36 months, leading to potential future exercises by the executive.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (stock option grant) and does not contain information that would fundamentally alter the investment thesis for InMed Pharmaceuticals Inc. It aligns management incentives with long-term shareholder value but does not provide new operational or financial data to warrant a change in investment recommendation. Investors should continue to hold based on the company's underlying fundamentals and strategic outlook.

Keywords

InMed Pharmaceuticals, INM, stock options, executive compensation, Form 4, beneficial ownership, equity grant, Shane Johnson